BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Šmahel M. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. Int J Mol Sci 2017;18:E1331. [PMID: 28635644 DOI: 10.3390/ijms18061331] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
Number Citing Articles
1 Quatrini L, Mariotti FR, Munari E, Tumino N, Vacca P, Moretta L. The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. Cancers (Basel) 2020;12:E3285. [PMID: 33172030 DOI: 10.3390/cancers12113285] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
2 Takeda Y, Yoshida S, Takashima K, Ishii-Mugikura N, Shime H, Seya T, Matsumoto M. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models. Cancer Sci 2018;109:2119-29. [PMID: 29791768 DOI: 10.1111/cas.13649] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
3 Wang X, Waschke BC, Woolaver RA, Chen Z, Zhang G, Piscopio AD, Liu X, Wang JH. Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas. Cancer Immunol Res 2019;7:1318-31. [PMID: 31235619 DOI: 10.1158/2326-6066.CIR-18-0875] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
4 Zhou Y, Bastian IN, Long MD, Dow M, Li W, Liu T, Ngu RK, Antonucci L, Huang JY, Phung QT, Zhao XH, Banerjee S, Lin XJ, Wang H, Dang B, Choi S, Karin D, Su H, Ellisman MH, Jamieson C, Bosenberg M, Cheng Z, Haybaeck J, Kenner L, Fisch KM, Bourgon R, Hernandez G, Lill JR, Liu S, Carter H, Mellman I, Karin M, Shalapour S. Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proc Natl Acad Sci U S A 2021;118:e2025840118. [PMID: 33602823 DOI: 10.1073/pnas.2025840118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Erdogdu IH. MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers. Gastroenterol Res Pract 2019;2019:4785098. [PMID: 30881447 DOI: 10.1155/2019/4785098] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
6 Zou J, Xia H, Zhang C, Xu H, Tang Q, Zhu G, Li J, Bi F. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy. Cancer Sci 2021;112:2664-78. [PMID: 33934451 DOI: 10.1111/cas.14932] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Minetto P, Guolo F, Pesce S, Greppi M, Obino V, Ferretti E, Sivori S, Genova C, Lemoli RM, Marcenaro E. Harnessing NK Cells for Cancer Treatment. Front Immunol 2019;10:2836. [PMID: 31867006 DOI: 10.3389/fimmu.2019.02836] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
8 Nakamura T, Ushigome H. Myeloid-Derived Suppressor Cells as a Regulator of Immunity in Organ Transplantation. Int J Mol Sci 2018;19:E2357. [PMID: 30103447 DOI: 10.3390/ijms19082357] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
9 Asahi Y, Hatanaka KC, Hatanaka Y, Kamiyama T, Orimo T, Shimada S, Nagatsu A, Sakamoto Y, Kamachi H, Kobayashi N, Fukai M, Taketomi A. Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma. Surg Today. 2020;50:931-940. [PMID: 32040618 DOI: 10.1007/s00595-020-01967-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
10 Ajina R, Zahavi DJ, Zhang YW, Weiner LM. Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies. Semin Cancer Biol 2020;65:28-37. [PMID: 31866479 DOI: 10.1016/j.semcancer.2019.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Dusenbery AC, Maniaci JL, Hillerson ND, Dill EA, Bullock TN, Mills AM. MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors. Am J Surg Pathol 2021;45:701-7. [PMID: 33739790 DOI: 10.1097/PAS.0000000000001653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Valentinuzzi D, Simončič U, Uršič K, Vrankar M, Turk M, Jeraj R. Predicting tumour response to anti-PD-1 immunotherapy with computational modelling. Phys Med Biol 2019;64:025017. [DOI: 10.1088/1361-6560/aaf96c] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
13 Mosca L, de Angelis A, Ronchi A, De Chiara A, Fazioli F, Ruosi C, Altucci L, Conte M, de Nigris F. Sarcoma Common MHC-I Haplotype Restricts Tumor-Specific CD8+ T Cell Response. Cancers 2022;14:3414. [DOI: 10.3390/cancers14143414] [Reference Citation Analysis]
14 Vuletić A, Mirjačić Martinović K, Tišma Miletić N, Zoidakis J, Castellvi-Bel S, Čavić M. Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer. Front Cell Dev Biol 2021;9:750022. [PMID: 34858978 DOI: 10.3389/fcell.2021.750022] [Reference Citation Analysis]
15 Nersesian S, Glazebrook H, Toulany J, Grantham SR, Boudreau JE. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. Front Immunol 2019;10:1782. [PMID: 31456796 DOI: 10.3389/fimmu.2019.01782] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
16 Gonzalez-Rodriguez AP, Villa-Álvarez M, Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez S. NK Cells in the Treatment of Hematological Malignancies. J Clin Med 2019;8:E1557. [PMID: 31569769 DOI: 10.3390/jcm8101557] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
17 Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, Azimi CS, Scheer AK, Randolph HE, Thompson TW, Zhang L, Iannello A, Mathur N, Jardine KE, Kirn GA, Bell JC, McBurney MW, Raulet DH, Ardolino M. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest 2018;128:4654-68. [PMID: 30198904 DOI: 10.1172/JCI99317] [Cited by in Crossref: 273] [Cited by in F6Publishing: 195] [Article Influence: 68.3] [Reference Citation Analysis]
18 Raskov H, Orhan A, Salanti A, Gaggar S, Gögenur I. Natural Killer Cells in Cancer and Cancer Immunotherapy. Cancer Lett 2021;520:233-42. [PMID: 34302920 DOI: 10.1016/j.canlet.2021.07.032] [Reference Citation Analysis]
19 Hodgins JJ, Khan ST, Park MM, Auer RC, Ardolino M. Killers 2.0: NK cell therapies at the forefront of cancer control. J Clin Invest 2019;129:3499-510. [PMID: 31478911 DOI: 10.1172/JCI129338] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 28.0] [Reference Citation Analysis]
20 Liu R, Dollinger E, Nie Q. Machine Learning of Single Cell Transcriptomic Data From anti-PD-1 Responders and Non-responders Reveals Distinct Resistance Mechanisms in Skin Cancers and PDAC. Front Genet 2021;12:806457. [PMID: 35178072 DOI: 10.3389/fgene.2021.806457] [Reference Citation Analysis]
21 Dibbern ME, Bullock TN, Jenkins TM, Duska LR, Stoler MH, Mills AM. Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition. Am J Surg Pathol 2020;44:1184-91. [PMID: 32496434 DOI: 10.1097/PAS.0000000000001506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Kanangat S, Seder CW, Pergande MR, Lobato GC, Fhied CL, Raouf MF, Liptay MJ, Borgia JA. Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions. Hum Immunol 2018;79:558-63. [PMID: 29656111 DOI: 10.1016/j.humimm.2018.04.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Yoo SH, Keam B, Ock CY, Kim S, Han B, Kim JW, Lee KW, Jeon YK, Jung KC, Chung EJ, Kwon SK, Ahn SH, Sung MW, Heo DS. Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients. Sci Rep 2019;9:7680. [PMID: 31118488 DOI: 10.1038/s41598-019-44206-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
24 Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol 2018;36:1412-8. [PMID: 29584545 DOI: 10.1200/JCO.2017.77.0388] [Cited by in Crossref: 131] [Cited by in F6Publishing: 84] [Article Influence: 32.8] [Reference Citation Analysis]
25 Wang Y, Li JJ, Ba HJ, Wang KF, Wen XZ, Li DD, Zhu XF, Zhang XS. Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma. Front Oncol 2019;9:857. [PMID: 31552181 DOI: 10.3389/fonc.2019.00857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Nakayama Y, Mimura K, Tamaki T, Shiraishi K, Kua LF, Koh V, Ohmori M, Kimura A, Inoue S, Okayama H, Suzuki Y, Nakazawa T, Ichikawa D, Kono K. Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer. Int J Oncol 2019;54:2030-8. [PMID: 31081058 DOI: 10.3892/ijo.2019.4779] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
27 Liang H, Liu X, Wang M. Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. Onco Targets Ther 2018;11:6189-96. [PMID: 30288054 DOI: 10.2147/OTT.S178497] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
28 Saini KS, Punie K, Twelves C, Bortini S, de Azambuja E, Anderson S, Criscitiello C, Awada A, Loi S. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert Opin Biol Ther 2021;21:945-62. [PMID: 34043927 DOI: 10.1080/14712598.2021.1936494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Yoo G, Park D, Kim Y, Chung C. New Insights into the Clinical Implications of Yes-Associated Protein in Lung Cancer: Roles in Drug Resistance, Tumor Immunity, Autophagy, and Organoid Development. Cancers (Basel) 2021;13:3069. [PMID: 34202980 DOI: 10.3390/cancers13123069] [Reference Citation Analysis]
30 Hänze J, Wegner M, Noessner E, Hofmann R, Hegele A. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer. Target Oncol 2020;15:377-90. [PMID: 32495158 DOI: 10.1007/s11523-020-00728-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
31 Ozpiskin OM, Zhang L, Li JJ. Immune targets in the tumor microenvironment treated by radiotherapy. Theranostics 2019;9:1215-31. [PMID: 30867826 DOI: 10.7150/thno.32648] [Cited by in Crossref: 38] [Cited by in F6Publishing: 46] [Article Influence: 12.7] [Reference Citation Analysis]
32 Abbas AB, Lin B, Liu C, Morshed A, Hu J, Xu H. Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor Activity. Int J Mol Sci 2019;20:E572. [PMID: 30699956 DOI: 10.3390/ijms20030572] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
33 Brossel H, Fontaine A, Hoyos C, Jamakhani M, Willems M, Hamaidia M, Willems L. Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma. Cancers (Basel) 2021;13:3211. [PMID: 34199066 DOI: 10.3390/cancers13133211] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Ahmed SR, Petersen E, Patel R, Migden MR. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Expert Rev Clin Pharmacol 2019;12:947-51. [PMID: 31524530 DOI: 10.1080/17512433.2019.1665026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
35 Wang X, Waschke BC, Woolaver RA, Chen SMY, Chen Z, Wang JH. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. Protein Cell 2020;11:472-82. [PMID: 32162275 DOI: 10.1007/s13238-020-00694-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
36 Curran T, Sun Z, Gerry B, Findlay VJ, Wallace K, Li Z, Paulos C, Ford M, Rubinstein MP, Chung D, Camp ER. Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities. Cancer Med 2021;10:1805-14. [PMID: 33560598 DOI: 10.1002/cam4.3753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Feola S, Capasso C, Fusciello M, Martins B, Tähtinen S, Medeot M, Carpi S, Frascaro F, Ylosmäki E, Peltonen K, Pastore L, Cerullo V. Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors. Oncoimmunology 2018;7:e1457596. [PMID: 30221051 DOI: 10.1080/2162402X.2018.1457596] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
38 Ruan WS, Feng MX, Xu J, Xu YG, Song CY, Lin LY, Li L, Lu YQ. Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis. Front Immunol 2020;11:1299. [PMID: 32719675 DOI: 10.3389/fimmu.2020.01299] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]